Overview

Craig D. Boyle, Ph.D., focuses his practice on patent prosecution in the pharmaceutical, life sciences, chemical, and biotechnology industries. In addition to the preparation and prosecution of patent applications, Craig manages patent portfolios and provides assistance with due diligence, freedom to operate, and landscape review.

Prior to joining Fish, Craig had over six years of experience as an intellectual property legal intern and an associate at an international law firm, where he assisted in the drafting and prosecution of patent applications, freedom to operate opinions, and due diligence analyses relating to small molecule therapeutics, oligonucleotides, antibody-drug-conjugates, polymers, and formulations.

Prior to his legal career, Craig spent 16 years as a medicinal chemist at Schering-Plough and Merck in roles ranging from laboratory scientist to cross-functional team leader, and successfully designed, synthesized, and advanced several novel drug candidates to clinical trials. His life science research experience spans several disease areas, including central nervous system, cardiovascular, and metabolic disorders.

Craig is a co-inventor of approximately 30 issued U.S. patents and 30 PCT applications and is an author of numerous scientific articles. He has received several awards, including the Research & Development Council of New Jersey Thomas Alva Edison Patent Award for the discovery of late-phase clinical Parkinson’s disease treatments and the Schering-Plough President’s Award for the discovery of a novel Alzheimer’s disease therapy.

Experience

U.S. Patents

Boyle, Craig D.; Lankin. Claire M.; Greenlee, William J.; Harris, Joel M.; “Substituted biaryl derivatives and methods of use thereof”; U.S. Patent 9,301,929, issued 2016.

Boyle, Craig; Greenlee, William; Chackalamannil, Samuel; Lankin, Claire; “Factor IXa inhibitors”; U.S. Patent 9,161,924, issued 2015.

Xia, Yan; Boyle, Craig D.; Greenlee, William J.; Chackalamannil, Samuel; Jayne, Charles Lee; “Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119”; U.S. Patent 8,907,095, issued 2014.

Neelamkavil, Santhosh Francis; Boyle, Craig D.; Chackalamannil, Samuel; Greenlee, William J.; Neustadt, Bernard R.; Stamford, Andrew W.; “Bicyclic heterocycle derivatives and use thereof as GPR119 modulators”; U.S. Patent 8,822,480, issued 2014.

Neelamkavil, Santhosh Francis; Boyle, Craig D.; Neustadt, Bernard R.; Chackalamannil, Samuel; Greenlee, William J.; “Bicyclic heterocycle derivatives and methods of use thereof”; U.S. Patent 8,815,876, issued 2014.

Shah, Unmesh; Boyle, Craig D.; Chackalamannil, Samuel; “Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11b-hydroxysteroid dehydrogenase type-1”; U.S. Patent 8,604,195, issued 2013.

Boyle, Craig D.; Lankin, Claire M.; Shah, Unmesh G.; Greenlee, William J.; Chackalamannil, Samuel; “Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders”; U.S. Patent 8,580,807, issued 2013.

Boyle, Craig D.; Chackalamannil, Samuel; Shah, Unmesh; Lankin, Claire M.; “6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11b-hydroxysteroid dehydrogenase type-I”; U.S. Patent 8,466,149, issued 2013.

Neustadt, Bernard R.; Lindo, Neil; Greenlee, William J.; Tulshian, Deen; Silverman, Lisa S.; Xia, Yan; Boyle, Craig D.; Chackalamannil, Samuel, “Adenosine A2a receptor antagonists”; U.S. Patent RE44,205, issued 2013.

Boyle, Craig D.; Chackalamannil, Samuel; Shah, Unmesh; Lachowicz, Jean E., “7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(- 1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine”; U.S. Patent 8,389,532, issued 2013.

Boyle, Craig D.; Chackalamannil, Samuel; Lankin, Claire M.; Shah, Unmesh G.; Neustadt, Bernard R.; Liu, Hong; Stamford, Andrew W., “Pyrimidinone Derivatives and Methods of Use Thereof”; U.S. Patent 8,318,751, issued 2012.

Neustadt, Bernard R.; Hao, Jinsong; Liu, Hong; Boyle, Craig D.; Chackalamannil, Samuel; Shah, Unmesh G.; Stamford, Andrew; Harris, Joel M., “Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine Adenosine A2a Receptor Antagonists”; U.S. Patent 7,709,492, issued 2010.

Boyle, Craig D.; Chackalamannil, Samuel; Shah, Unmesh; Lachowicz, Jean E., “7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine”; U.S. Patent 7,572,802, issued 2009.

Chackalamannil, Samuel; Wang, Yuguang; Boyle, Craig D.; Stamford, Andrew W., “Xanthine Phosphodiesterase V Inhibitors”; U.S. Patent 7,531,544, issued 2009.

Neustadt, Bernard R.; Boyle, Craig D.; et al., “2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine Adenosine A2A Receptor Antagonists”; U.S. Patent 7,465,740, issued 2008.

Neustadt, Bernard R.; Boyle, Craig D.; et al., “2-Alkynyl- and 2-Alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine Adenosine A2A Receptor Antagonists”; U.S. Patent 7,368,449, issued 2008.

Ghosal, Anima; Boyle, Craig D.; et al., “Metabolite of Xanthine Phosphodiesterase 5 Inhibitor and Derivatives Thereof Useful for Treatment of Erectile Dysfunction”; U.S. Patent 7,312,223, issued 2007.

Chackalamannil, Samuel; Wang, Yuguang; Boyle, Craig D.; Stamford, Andrew W., “Xanthine Phosphodiesterase V Inhibitors”; U.S. Patent 7,268,141, issued 2007.

Dahanukar, Vilas H.; Boyle, Craig D.; et al., “Xanthine Phosphodiesterase V Inhibitor Polymorphs”; U.S. Patent 7,192,962, issued 2007.

Boyle, Craig D.; Chackalamannil, Samuel; Greenlee, William J.; Shah, Unmesh; Xia, Yan, “Adenosine A2A Receptor Antagonists”; U.S. Patent 6,916,811, issued 2005.

Neustadt, Bernard R.; Boyle, Craig D.; et al., “2-Alkynyl- and 2-Alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine Adenosine A2A Receptor Antagonists”; U.S. Patent 6,897,217, issued 2005.

Neustadt, Bernard R.; Boyle, Craig D.; et al., “Adenosine A2A Receptor Antagonists”; U.S. Patent 6,897,216, issued 2005.

Boyle, Craig D.; Greenlee, William J.; Chackalamannil, Samuel, “Muscarinic Antagonists”; U.S. Patent 6,890,936, issued 2005.

Chackalamannil, Samuel; Wang, Yuguang; Boyle, Craig D.; Stamford, Andrew W., “Xanthine Phosphodiesterase V Inhibitors”; U.S. Patent 6,821,978, issued 2004.

Stamford, Andrew W.; Boyle, Craig D.; Huang, Ying, “Substituted Imidazole Neuropeptide Y Y5 Receptor Antagonists”; U.S. Patent 6,632,828, issued 2003.

Neustadt, Bernard R.; Boyle, Craig D.; et al., “Adenosine A2A Receptor Antagonists”; U.S. Patent 6,630,475, issued 2003.

Stamford, Andrew W.; Boyle, Craig D.; Huang, Ying, “Substituted Imidazole Neuropeptide Y Y5 Receptor Antagonists”; U.S. Patent 6,444,687, issued 2002.

Lowe, Derek B.; Boyle, Craig D.; et al., “Muscarinic Antagonists”; U.S. Patent 6,043,255, issued 2000.

Lowe, Derek B.; Boyle, Craig D.; et al., “Preparation of Muscarinic Antagonists”; U.S. Patent 5,889,006, issued 1999.